FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. PMID 41123227 · Cancer Med · 2025-Oct The study is an open-label, non-randomized pragmatic clinical trial. It is not randomized, and the phase is not explicitly stated as Phase III/IIIb or Phase II/III. While it reports time-to-event endpoints (OS, PFS), the primary endpoint was safety, and it does not meet the core criteria of a randomized Phase III/IIIb or Phase II/III trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. PMID 41117518 · Cancer Med · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Effect of Life Coaching on Post-Traumatic Growth and Well-Being in Breast Cancer Survivors: A Randomized Controlled Trial. PMID 41068064 · Psychooncology · 2025-Oct The study is a randomized controlled trial in breast cancer survivors but evaluates a life coaching intervention, not a drug intervention. The primary endpoints are psychosocial outcomes (post-traumatic growth, fear of cancer recurrence, quality of life), not time-to-event efficacy endpoints. Phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial. PMID 41033278 · ESMO Open · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling. PMID 41032624 · Sci Transl Med · 2025-Oct The record describes a non-randomized (single-arm) clinical trial. While it is oncologic, human, involves a drug, and has publication types indicating Phase II/III, the lack of randomization and the absence of a time-to-event efficacy endpoint make it ineligible for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. PMID 41023484 · Nat Med · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Yangxiao Fukang granule in the treatment of stage Ⅲ hepatitis B related liver cancer: study protocol for a randomized controlled trial. PMID 41015811 · J Tradit Chin Med · 2025-Oct 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial. PMID 40998687 · Eur Urol Oncol · 2025-Oct This is an original report of a Phase 2/3 randomized trial (THUNDER) in oncology (prostate cancer). It is human, randomized, and reports original results. However, it is excluded because: 1) The intervention is a diagnostic imaging procedure (PSMA PET/CT) versus conventional imaging, not a drug-containing therapeutic intervention. 2) The primary endpoint reported is stage migration (diagnostic accuracy), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the required criteria for inclusion in this Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). PMID 40997746 · ESMO Open · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Feasibility, acceptability, and experienced benefits of kind acts and gratitude letter interventions among collectivist and individualist culture cancer patients and caregivers: A pilot study. PMID 40986989 · Eur J Oncol Nurs · 2025-Oct This is a randomized pilot/feasibility study of psychosocial interventions (kind acts, gratitude letters) in cancer patients. It is not a Phase III/IIIb or Phase II/III trial, does not involve a drug-containing intervention, and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcomes are feasibility, acceptability, and qualitative perceived benefits. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial. PMID 40960276 · Liver Int · 2025-Oct The study is a randomized Phase II/III-like trial (implied by 'randomised' and comparison to standard TACE) but lacks explicit phase designation. The primary endpoint is disease control rate (DCR), a categorical outcome at a fixed time point, not a time-to-event endpoint. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data. PMID 40957133 · Thromb Res · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of mat Pilates on postural control in breast cancer survivors receiving endocrine therapy: a randomized controlled clinical trial. PMID 40954654 · J Bodyw Mov Ther · 2025-Oct Study is a randomized trial in breast cancer survivors but does not meet key eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial, the intervention is non-drug (Pilates exercise), and the primary endpoints are not time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study. PMID 40929800 · Thromb Res · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. PMID 40923969 · J Thorac Oncol · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial. PMID 40913172 · Nat Med · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. PMID 40908381 · Drugs · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. PMID 40897974 · Nat Med · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Early Results of Hypofractionated Chemoradiation in Cervical Cancer with 44 Gy/ 20 F vs 45 Gy/ 25 F: A Phase II, Open-Label, Randomised Controlled Trial (HYPOCx-iRex Trial). PMID 40897075 · Clin Oncol (R Coll Radiol) · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A Meta-Analysis. PMID 40886492 · Clin Genitourin Cancer · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. PMID 40885199 · Lancet Oncol · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer. PMID 40845250 · J Clin Oncol · 2025-Oct Record meets all eligibility criteria: oncology, human, randomized, phase III/definitive, time-to-event endpoint (PFS), drug intervention, original result report. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer. PMID 40839957 · Gynecol Oncol · 2025-Oct This is a randomized, drug-intervention (vaccine) study in human oncology (cervical cancer). However, it is explicitly described as a 'pilot study' with a small sample size (N=15), and the primary outcomes reported are immunogenicity, safety, and absence of recurrence (binary), with no time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier curves/HR presented. It does not meet the definitive phase (III/IIIb or II/III) or time-to-event efficacy requirements. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fluorescence quantitative assessment of blood perfusion in the gastric conduit to reduce anastomotic leakage after esophagectomy: a randomized controlled trial. PMID 40835759 · Surg Endosc · 2025-Oct The study is a randomized trial in oncology (esophageal cancer) with a time-to-event endpoint (survival) and reports primary results, but it does not meet the core eligibility criterion of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Qu-yu-jie-du decoction maintenance therapy improves postoperative survival in metastatic colorectal cancer: a single-center randomized trial with 36-month follow-up. PMID 40815944 · Phytomedicine · 2025-Oct The record is an original result report of a randomized trial in oncology with a drug intervention and a key time-to-event efficacy endpoint (DFS). However, the explicit trial phase is not provided in the title, abstract, or metadata. It is described as a 'single-center randomized trial' without specifying Phase II, III, or other. The deterministic review flagged 'phase3_evidence_unclear' as the reason for needing review. Without explicit confirmation of a Phase III/IIIb or Phase II/III trial, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure. PMID 40796015 · Radiother Oncol · 2025-Oct The record describes a phase III RCT with a drug intervention, but the abstract is about radiotherapy quality assurance procedures and their impact on delineation accuracy and dosimetry, not the trial's clinical efficacy results. There is no signal of time-to-event outcome data (e.g., OS, PFS) being reported in this specific publication. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study. PMID 40795480 · Breast · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Addressing health literacy gaps in adjuvant endocrine therapy adherence: Post hoc insights from a randomized remote monitoring trial. PMID 40779883 · Breast · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trial. PMID 40775446 · Br J Cancer · 2025-Oct Study is a randomized oncology trial with original results, but it lacks a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer. PMID 40745221 · Br J Cancer · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial. PMID 40730749 · Dig Liver Dis · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema. PMID 40699530 · Ann Surg Oncol · 2025-Oct The record describes a randomized trial in breast cancer (oncology, human, randomized, original primary results) but the intervention is bioimpedance spectroscopy screening (a diagnostic/prophylactic management strategy) not a drug-containing therapy. The primary endpoint is progression to chronic lymphedema (a clinical outcome), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The abstract does not report Kaplan-Meier curves, hazard ratios, or any time-to-event analysis, focusing instead on cross-sectional baseline assessments. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program. PMID 40673944 · Epilepsia · 2025-Oct 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial. PMID 40670666 · Br J Cancer · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. PMID 40652442 · Neurol Ther · 2025-Oct The record describes a study in relapsing multiple sclerosis, not a human malignant neoplasm (oncology). The primary/time-to-event efficacy endpoint is not OS, PFS, DFS, EFS, RFS, TTP, or another classic oncology time-to-event outcome. The study is a randomized, Phase III trial with a drug intervention, but fails the core oncology and endpoint criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial. PMID 40639766 · Radiother Oncol · 2025-Oct The trial is a randomized Phase III oncology trial, but it fails two critical inclusion criteria: (1) the primary/key secondary endpoint is not a standard time-to-event efficacy endpoint (it is a quality-of-life/toxicity endpoint), and (2) the intervention is non-drug only (radiation therapy). Therefore, it is not eligible for this cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. PMID 40632620 · Leuk Lymphoma · 2025-Oct The study is an oncology trial with a drug intervention and reports original primary results. However, it is explicitly a Phase 1/2 trial (not Phase III/IIIb) and is single-arm (not randomized). The abstract reports response rates (ORR, CR) as the primary efficacy endpoints, with no mention of a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Growing Potential of Thermal Ablation for Colorectal Liver Metastases. PMID 40616649 · J Surg Oncol · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Undertreated Volume and Tumor Morphology as Predictors of Outcome Following Thermal Ablation of 3-7-cm Hepatocellular Carcinoma. PMID 40609677 · J Vasc Interv Radiol · 2025-Oct The study is an original analysis from a randomized trial but does not present a drug-containing intervention as the primary focus of this report (ThermoDox is mentioned as part of the prior trial, but this analysis is a retrospective sub-study on imaging predictors). More critically, the primary endpoints are predictors of local recurrence and survival via univariate/multivariate analysis (p-values), not a formal time-to-event efficacy report with Kaplan-Meier curves, hazard ratios, or survival probabilities as the primary outcome. The 'survival' outcome is mentioned as a correlation, not as a reported time-to-event endpoint with event rates or curves. Therefore, it does not meet the time-to-event efficacy requirement for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial. PMID 40545499 · Chin J Integr Med · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. PMID 40543844 · Ann Oncol · 2025-Oct 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial. PMID 40541863 · Ann Oncol · 2025-Oct The report is a secondary analysis of health-related quality of life from a Phase III randomized trial. It does not present primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS) with Kaplan-Meier or HR. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance). PMID 40532782 · J Thorac Cardiovasc Surg · 2025-Oct The study is a randomized trial in oncology with time-to-event efficacy endpoints (DFS, RFS) and original results, but it does not involve a drug-containing intervention. The intervention is surgical (lobar vs. sublobar resection) and the analysis examines the extent of lymph node dissection. Therefore, it fails the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features. PMID 40474660 · Acta Radiol · 2025-Oct This is an oncology randomized trial in humans with original results, but it is excluded because the intervention is a non-drug predictive model (radiomics and clinical features) for guiding diagnosis/treatment, and it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) using Kaplan-Meier or HR. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1. PMID 40473108 · J Thorac Oncol · 2025-Oct The record is a randomized trial in human oncology with a drug intervention and a time-to-event endpoint (treatment-free survival). However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Additionally, while the endpoint is time-to-event and derived from KM curves, it is treatment-free survival, which is not one of the primary/key secondary endpoints listed in the criteria (OS, PFS, DFS, EFS, RFS, TTP). Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer. PMID 40434336 · J Perianesth Nurs · 2025-Oct The study is a randomized controlled trial in oncology (lung cancer surgery) with a drug intervention (ropivacaine and esketamine), but it is a perioperative analgesia study, not a definitive therapeutic trial evaluating a cancer-specific time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease. PMID 40401357 · J Clin Pharmacol · 2025-Oct The study is a pharmacokinetic and exposure-response analysis from a Phase III trial in Crohn's disease (inflammatory bowel disease), which is a non-oncology condition. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS) for a human malignant neoplasm. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial. PMID 40374989 · Virchows Arch · 2025-Oct The report is a pathological analysis of the COLOPEC trial (which is a randomized trial with a drug intervention and time-to-event endpoints), but it is not the primary/definitive efficacy report of the trial itself. Furthermore, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided metadata, which is a required criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40348701 · Eur Urol · 2025-Oct The record describes a phase 3 randomized trial of a surgical technique (NeuroSAFE-guided vs standard RARP) for localized prostate cancer. While it meets criteria for oncology, human, randomized, and phase 3, it lacks a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR data, focusing instead on functional outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial. PMID 40289847 · Arthritis Rheumatol · 2025-Oct The study is a randomized controlled trial of a tumor necrosis factor inhibitor in rheumatoid arthritis, which is not an oncology/malignant neoplasm indication. Therefore, it does not meet the primary oncology eligibility criterion for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |